Navigation Links
Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Date:3/30/2011

SAN MATEO, Calif., March 30, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming cenderitide presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5th.

Location: Ernest N. Morial Convention Center, Hall F

Date: Sunday, April 3, 2011

Time: 10:00 AM -11:15 AM (CDT)

Poster Presentation: Board #256

Presenter: Hsiao D. Lieu, MD, FACC

Title: "A Phase II, Dose-Ranging Study with CD-NP, a Chimeric Natriuretic Peptide, in Acute Decompensated Heart Failure Patients with Renal Compromise"

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
2. Osseon™ Therapeutics Introduces Osseoflex® BT Steerable Bone Tamp
3. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
4. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
5. Reportlinker Adds Therapeutics for Immune System Disorders
6. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
7. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
8. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
9. Echo Therapeutics Announces 2010 Financial Results
10. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
11. Reportlinker Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... 5, 2017 The Cincinnati ... Pharmacy, Inc. (NYSE: DPLO), has been awarded a Top ... Results are based on an employee survey administered ... and workplace improvement. The survey measures several aspects of workplace ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology:
(Date:6/26/2017)... , ... June 26, 2017 , ... Antoine Dental Center is now offering ... in tooth replacement and act as a support for prosthetic teeth, such as crowns, bridges, ... existing bone and becomes a sturdy, lasting new root for the tooth. , Several ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... a recent review of government data released by the United Soybean Board. ... practices, Maryland’s soybean farmers have increased their productivity on less land per bushel, ...
(Date:6/26/2017)... TX (PRWEB) , ... June 26, 2017 , ... ... their coding staff, and consumers are seeing lots of red these days. According ... contain inaccurate charges that result from medical coding errors(1). Some studies point to ...
(Date:6/25/2017)... ... June 25, 2017 , ... FCPX LUT Vintage Volume 2 for Final Cut ... LUT Vintage Volume 2 contains 60 different color-grade presets, giving editors multiple options for ... blurs to single out subjects, plus much more. FCPX LUT Vintage Volume 2 is ...
(Date:6/25/2017)... , ... June 25, 2017 , ... An increase in ... growing foliage and plants, and along with that; a humdinger of an allergy season. ... it also means an increase in misery-causing grass and weed pollen. , “Our ...
Breaking Medicine News(10 mins):